Latest News

Category: ASX

See all

Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®

ASX, News,

Telix today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S.) based clinical stage company developing therapeutic radiopharmaceuticals for primary and metastatic bone...

Read more

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

ASX, News,

Telix and Paris-based Mauna Kea Technologies, today announce an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance through a strategic €6.0 million (AU$9.6 million) investment to develop new...

Read more

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

ASX, Clinical, News,

Telix today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC)...

Read more

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region

ASX, News,

Telix today announces it has signed an exclusive agreement with Denmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix’s investigational prostate cancer imaging agent, Illuccix® (TLX591-CDx, Kit for...

Read more

Telix Completes Acquisition of Lightpoint Medical

ASX, News,

Telix, today announces the completion of the acquisition of Lightpoint Medical and its SENSEI® radio-guided surgery business (refer to announcement on 21 June...

Read more

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

ASX, Clinical, News,

Telix today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic...

Read more

Activities Report and Appendix 4C for the quarter ended 30 September 2023

ASX, News,

Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise...

Read more

Telix Quarterly Results and Investor Call / Webcast Notification

ASX, News,

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 September 2023 on Wednesday 18 October...

Read more

Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company

ASX, News,

Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise...

Read more

Telix Half-Year Results 2023 and Investor Call / Webcast Notification

ASX, News,

Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August...

Read more